Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

China Aoxing’s Revenues Climb; Net Income Still Negative

publication date: May 18, 2009

China Aoxing Pharmaceutical Company (中国奥星药业) reported its 2008 third quarter (ended March 31, 2009) results, saying revenues rose 85% to $1.6 million, largely because the company acquired Shijiazhuang Lerentang Pharmaceutical Company Ltd. (LRT) in 2008. LRT is a TCM drug company that, like China Aoxing, focuses on pain medications. China Aoxing said its operating loss in Q3 was $700,000 in Q3, about half the year-earlier period. More details...

Stock Symbol: (OTCBB: CAXG)



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital